Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Semaglutide patents expired across a cluster of major markets simultaneously in early 2026, including India, Canada, and China representing markets that together account for a substantial share of global diabetes and obesity patients
And in 2023, Eli Lilly acquired Versanis for their drug candidate bimagrumab, a monoclonal antibody that appears to be effective in preserving muscle mass during weight loss
It seems people are more comfortable saying they microdose GLP-1s because it signals theyre not taking the drug for vanitys sake
Furthermore, research published in the journal Obesity Science & Practice highlighted the benefits of semaglutide for long-term weight maintenance, demonstrating sustained reductions in body weight and improvements in obesity-related comorbidities over time
US$ 24.77
US$ 28.45
US$ 26.14
US$ 25.71
